News
Dr Ken Romeril, Multiple Myeloma founder, Member of the NZ Order of Merit, advocates for the desperate need for access to modern medicines for myeloma sufferers.
https://www.stuff.co.nz/opinion/300759926/miracle-medicines-a-cancer-specialist-sends-a-message-to-pharmac
BLOOD CANCER PATIENTS IMPLORE PHARMAC TO FUND DESPERATELY NEEDED MEDICINE
MEDIA RELEASE 7 September 2022 New Zealanders living with multiple myeloma, a deadly, relapsing/remitting blood cancer, are mounting a major,...
Multiple Myeloma Research Review
Multiple_Myeloma_Research_Review_Issue_43Download
Rachel Smalley: 1,000 kiwis will die while Pharmac takes eight months to make a decision
OPINION: How long does it take you to make a decision about whether or not to buy something? You’ve got all the information in front of you. You...
Multiple Myeloma Queenstown Summit
In August 2022, Myeloma New Zealand is hosting its 4th Myeloma Summit for medical professionals in Queenstown. Held in 2016,2018, 2020 and now again...
Multiple Myeloma Research Review
Multiple_Myeloma_Research_Review_Issue_42Download
Multiple Myeloma CEO, Dr Ken Romeril, on The AM Show this morning, calling for a release of the independent report on Pharmac
Please click on this link to watch the interview: https://fb.watch/cWyMuvV_QO/
DOCTOR CALLS ON MINISTER LITTLE TO RELEASE ‘BURIED’ INDEPENDENT REPORT ON PHARMAC
MEDIA RELEASE DOCTOR CALLS ON MINISTER LITTLE TO RELEASE ‘BURIED’ INDEPENDENT REPORT ON PHARMAC The final report of the Independent Pharmac Review...
Dr Ken Romeril, of Wellington, receives his MNZM for services to haematology.
Congratulations on your very well-deserved appointment to The New Zealand Order of Merit for your services to Haematology! Dr Ken Romeril is a...
Updates on the Rapidly Changing Therapeutic Landscape in Multiple Myeloma
As we continue to understand more about the biology of multiple myeloma (MM) and the number of treatment options for patients with MM continues to...
Multiple Myeloma Media Release
The Cancer Control Agency’s analysis of the gap between Australia and New Zealand in funding 18 selected medicines with substantial clinical benefit...
Decision on access criteria for oral COVID-19 treatments
The Access Criteria for the oral antiviral COVID-19 treatments, nirmatrelvir with ritonavir (Paxlovid) and molnupiravir (Lagevrio) has been...